Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Amylin, Lilly, Alkermes Shares Fall on Bydureon Delay

GlaxoSmithKline Plc’s Avandia
The guidelines were released in December 2008 while the agency was facing criticism for failing to recognize the heart risks of GlaxoSmithKline Plc’s Avandia, seen here, which was found to increase heart attack risk in 2007 after eight years on the market. Photographer: JB Reed/ Bloomberg

Oct. 20 (Bloomberg) -- Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. dropped in trading after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.

The Food and Drug Administration “blindsided” the companies late yesterday by calling for a study assessing the heart risks for the new drug Bydureon, said Phil Nadeau, an analyst with Cowen & Co. in New York. Amylin was the biggest loser, plunging $9.46, or 46 percent, to $11.03 at 4 p.m. New York time in Nasdaq Stock Market composite trading, its biggest single-day decline in 12 years.

Had Bydureon been approved, Nadeau estimated 2011 sales of $420 million. The drug now will be delayed by as long as 20 months based on a timetable Amylin outlined in a conference call with analysts, he said. Amylin Chief Executive Officer Daniel Bradbury said the company has the cash resources to get through the longer time to bring the drug to market.

“It seems like another instance where the FDA surprised a company and it doesn’t seem like Amylin did anything wrong,” Nadeau said yesterday by telephone. “Seems like they got blindsided and that’s happening more and more.”

The agency hadn’t requested new studies when it declined to approve Amylin’s Bydureon application on March 15 and asked for more information about a risk-management plan. Amylin plans to respond to the FDA with the results of the heart-risk research by end of 2011, Bradbury said yesterday on a conference call.

While Amylin prepares the heart study, competitor Novo Nordisk S/A’s diabetes drug Victoza will gain further market share, Nadeau said.

Alkermes, Lilly, Novo Shares

Alkermes, based in Waltham, Massachusetts, dropped $4, or 28 percent, to $10.50 on the Nasdaq exchange, its biggest single-day decline since July 1, 2002. Indianapolis-based Lilly fell $1.44, or 3.9 percent, to $36.01 in New York Stock Exchange composite trading, the company’s biggest single-day decline in 10 months. The shares of Bagsvaerd, Denmark-based Novo gained the most in two years in Copenhagen trading.

MannKind Corp., a Valencia, California-based company developing an insulin inhaler for diabetes, fell 35 cents, or 5.1 percent, to $6.57 in Nasdaq trading. The FDA is scheduled to decide whether to approve the company’s product, Afrezza, by Dec. 29.

24 Million Diabetics

Almost 24 million Americans have diabetes, which occurs when people don’t have sufficient amounts of the hormone insulin, or are resistant to it, hampering their ability to convert blood sugar to energy. The FDA requires makers of new diabetes drugs to prove they aren’t tied to an increase in heart attacks and deaths.

The guidelines were released in December 2008 while the agency was facing criticism for failing to recognize the heart risks of GlaxoSmithKline Plc’s Avandia, which was found to increase heart attack risk in 2007 after eight years on the market. Last month, the FDA restricted use of Avandia, once the world’s best-selling diabetes drug. Glaxo is based in London.

Amylin had started producing Bydureon to build inventory in anticipation of an approval, Bradbury said. The excess inventory may be used if the drug is approved in Europe, or in the new clinical trials, he said.

Byetta, a synthetic version of a substance found in the saliva of the Gila monster, stimulates pancreas cells to produce the hormone insulin when blood sugar is high. A twice-daily injection, it had worldwide sales of $796.5 million in 2009.

Newer Class

Byetta is a so-called GLP-1 analogue, a newer class of diabetes medicine that boosts insulin production in patients with Type 2 diabetes. Victoza, a GLP-1 analogue from Novo, was approved Jan. 25 by the FDA with required warnings for thyroid cancer and pancreatitis.

Roche Holding AG of Basel, Switzerland, said Sept. 10 it had told doctors to stop giving its experimental GLP-1 analogue taspoglutide to patients in clinical trials after side effects such as nausea and vomiting led many to drop out of the studies.

Amylin plans to report third-quarter earnings within the next few weeks, pending its assessment of the effect of the FDA’s decision on Bydureon, the company said in a statement.

Lilly markets Byetta outside the U.S. and co-markets it with Amylin in the U.S. The drug was developed by Amylin, and the technology enabling it to be used in a longer-acting form was developed by Alkermes. Alkermes will receive royalties of about 8 percent on Bydureon sales.

To contact the reporters on this story: Drew Armstrong in Washington at; Rob Waters in San Francisco at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.